JP2024099745A5 - - Google Patents
Info
- Publication number
- JP2024099745A5 JP2024099745A5 JP2024071889A JP2024071889A JP2024099745A5 JP 2024099745 A5 JP2024099745 A5 JP 2024099745A5 JP 2024071889 A JP2024071889 A JP 2024071889A JP 2024071889 A JP2024071889 A JP 2024071889A JP 2024099745 A5 JP2024099745 A5 JP 2024099745A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oligonucleotide
- alcoholic steatohepatitis
- rcd
- cirrhosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514769P | 2017-06-02 | 2017-06-02 | |
| US62/514,769 | 2017-06-02 | ||
| US201862670698P | 2018-05-11 | 2018-05-11 | |
| US62/670,698 | 2018-05-11 | ||
| PCT/US2018/035721 WO2018223081A1 (en) | 2017-06-02 | 2018-06-01 | Oligonucleotide compositions and methods of use thereof |
| JP2019566839A JP7557941B2 (ja) | 2017-06-02 | 2018-06-01 | オリゴヌクレオチド組成物及びその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566839A Division JP7557941B2 (ja) | 2017-06-02 | 2018-06-01 | オリゴヌクレオチド組成物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024099745A JP2024099745A (ja) | 2024-07-25 |
| JP2024099745A5 true JP2024099745A5 (enExample) | 2025-08-08 |
Family
ID=64456268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566839A Active JP7557941B2 (ja) | 2017-06-02 | 2018-06-01 | オリゴヌクレオチド組成物及びその使用方法 |
| JP2024071889A Pending JP2024099745A (ja) | 2017-06-02 | 2024-04-25 | オリゴヌクレオチド組成物及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566839A Active JP7557941B2 (ja) | 2017-06-02 | 2018-06-01 | オリゴヌクレオチド組成物及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11597927B2 (enExample) |
| EP (1) | EP3630789A4 (enExample) |
| JP (2) | JP7557941B2 (enExample) |
| CN (2) | CN110997692B (enExample) |
| CA (1) | CA3065523A1 (enExample) |
| TW (1) | TW201904587A (enExample) |
| WO (1) | WO2018223081A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| SG10201912902TA (en) | 2015-10-09 | 2020-02-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| CN114685589A (zh) | 2016-03-13 | 2022-07-01 | 波涛生命科学有限公司 | 用于亚磷酰胺和寡核苷酸合成的组合物和方法 |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| ES2837076T3 (es) | 2016-09-01 | 2021-06-29 | Proqr Therapeutics Ii Bv | Oligonucleótidos para la edición de ARN de cadena sencilla modificados químicamente |
| WO2018098264A1 (en) | 2016-11-23 | 2018-05-31 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| WO2018223081A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2018223056A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| JP7402696B2 (ja) | 2017-06-21 | 2023-12-21 | ウェイブ ライフ サイエンシズ リミテッド | 合成のための化合物、組成物、及び方法 |
| EP3664816A4 (en) | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES |
| AU2018333065B2 (en) | 2017-09-18 | 2024-04-18 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
| WO2019075357A1 (en) | 2017-10-12 | 2019-04-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| UY38003A (es) * | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| WO2019126144A1 (en) | 2017-12-22 | 2019-06-27 | North Carolina State University | Polymeric fluorophores, compositions comprising the same, and methods of preparing and using the same |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| EP3899015A1 (en) * | 2018-12-19 | 2021-10-27 | Astrazeneca AB | Biomarker of pnpla3 expression |
| TW202122093A (zh) * | 2019-08-29 | 2021-06-16 | 大陸商蘇州瑞博生物技術股份有限公司 | 化合物、藥物綴合物、試劑盒及其用途 |
| JP7757277B2 (ja) * | 2019-10-14 | 2025-10-21 | アストラゼネカ・アクチエボラーグ | Ｐｎｐｌａ３発現のモジュレーター |
| IL294515A (en) | 2020-01-31 | 2022-09-01 | Avilar Therapeutics Inc | Compounds bind asgpr to degrade extracellular proteins |
| KR20230016201A (ko) | 2020-05-22 | 2023-02-01 | 웨이브 라이프 사이언시스 리미티드 | 이중 가닥 올리고뉴클레오티드 조성물 및 이와 관련된 방법 |
| CN112121152B (zh) * | 2020-09-25 | 2021-06-22 | 南京大学 | 利司那肽在制备抗肿瘤药物中的应用 |
| WO2022109030A1 (en) * | 2020-11-17 | 2022-05-27 | Skyhawk Therapeutics, Inc. | Rna-targeting splicing modifiers for treatment of pnpla3-associated conditions and diseases |
| WO2022221430A1 (en) | 2021-04-14 | 2022-10-20 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating pnpla3 expression |
| AU2022268925A1 (en) | 2021-05-03 | 2023-11-16 | Avilar Therapeutics, Inc. | Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins |
| WO2023009554A1 (en) * | 2021-07-26 | 2023-02-02 | Avilar Therapeutics, Inc. | Methods to reduce adverse effects of gene or biologics therapy |
| US20250154504A1 (en) | 2022-02-14 | 2025-05-15 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| EP4623084A1 (en) | 2022-11-24 | 2025-10-01 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| CN120239747A (zh) * | 2022-12-07 | 2025-07-01 | 上海舶望制药有限公司 | 用于抑制含Patatin样磷脂酶结构域蛋白3(PNPLA3)表达的组合物和方法 |
| CA3276262A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| CN121039141A (zh) * | 2023-03-01 | 2025-11-28 | 波涛生命科学有限公司 | 用于rna干扰的双链寡核苷酸组合物及其相关方法 |
| WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| AU2024246572A1 (en) | 2023-03-27 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| CN116500278A (zh) * | 2023-05-05 | 2023-07-28 | 山东第一医科大学第二附属医院 | 标志物在制备诊断或辅助诊断缺血性脑卒中产品中的应用 |
| AR132964A1 (es) | 2023-06-16 | 2025-08-13 | Proqr Therapeutics Ii Bv | Oligonucleótidos antisentido para el tratamiento de enfermedades neurodegenerativas |
| WO2025015335A1 (en) | 2023-07-13 | 2025-01-16 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2025128799A1 (en) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| WO2025199466A1 (en) | 2024-03-22 | 2025-09-25 | Purdue Research Foundation | Liver-specific asialoglycoprotein receptor targeting ligands, conjugates comprising same, and related compositions and methods of use |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216168A (en) | 1992-04-01 | 1993-06-01 | G. D. Searle & Co. | 2- and 3- amino and azido derivatives of 1,5-iminosugars |
| AU2002317087A1 (en) | 2001-06-29 | 2003-03-03 | Micrologix Biotech Inc. | Phosphoramide containing nucleic acid-based compounds and libraries as antivirals |
| US8232383B2 (en) | 2002-02-20 | 2012-07-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP2333062A1 (en) | 2002-07-10 | 2011-06-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA-interference by single-stranded RNA molecules |
| WO2004014933A1 (en) | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
| JP2005089441A (ja) | 2003-08-08 | 2005-04-07 | Toudai Tlo Ltd | 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法 |
| JP4580870B2 (ja) | 2003-09-02 | 2010-11-17 | 株式会社キラルジェン | リボヌクレオチド又はリボヌクレオチド誘導体の製造方法 |
| WO2005028494A1 (ja) | 2003-09-02 | 2005-03-31 | Takeshi Wada | ５'-ホスフィチル化モノマーおよびh-ホスホネートオリゴヌクレオチド誘導体の製造方法 |
| WO2005070859A1 (ja) | 2004-01-27 | 2005-08-04 | Takeshi Wada | フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| WO2005085272A1 (ja) | 2004-03-05 | 2005-09-15 | Takeshi Wada | ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| JP4865544B2 (ja) | 2004-03-25 | 2012-02-01 | 株式会社キラルジェン | 立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法 |
| ATE498685T1 (de) | 2004-06-28 | 2011-03-15 | Univ Western Australia | Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon |
| US7427675B2 (en) | 2004-08-23 | 2008-09-23 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
| ES2332139T3 (es) | 2005-11-23 | 2010-01-27 | F. Hoffmann-La Roche Ag | Polinucleotidos con mimetico de fosfato. |
| CN101663313B (zh) | 2007-04-18 | 2013-08-21 | 霍夫曼-拉罗奇有限公司 | 具有α-磷酸模拟物的核苷酸 |
| US8883752B2 (en) | 2008-10-24 | 2014-11-11 | Isis Pharmaceuticals, Inc. | 5′ and 2′ BIS-substituted nucleosides and oligomeric compounds prepared therefrom |
| WO2010048585A2 (en) | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| CN102574888A (zh) | 2009-09-16 | 2012-07-11 | 株式会社启拉坚 | 用于rna及其衍生物的合成的新型保护基 |
| WO2011109427A2 (en) | 2010-03-01 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Improving the biological activity of sirna through modulation of its thermodynamic profile |
| WO2011108682A1 (ja) | 2010-03-05 | 2011-09-09 | 国立大学法人 東京大学 | リボヌクレオシドホスホロチオエートの製造方法 |
| WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| EP2616543A1 (en) * | 2010-09-15 | 2013-07-24 | Alnylam Pharmaceuticals, Inc. | MODIFIED iRNA AGENTS |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| JP6093924B2 (ja) | 2010-11-30 | 2017-03-15 | 株式会社Wave Life Sciences Japan | ２’−ｏ−修飾ｒｎａ |
| US9416154B2 (en) | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| US20140323709A1 (en) | 2011-12-12 | 2014-10-30 | National Cerebral And Cardiovascular Center | Oligonucleotide and therapeutic agent for hyperlipidemia containing same as active ingredient |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| CN104661664B (zh) * | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| MX2016009290A (es) * | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
| EP3221451A1 (en) | 2014-11-17 | 2017-09-27 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| CA2976445A1 (en) * | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| CN116004624A (zh) | 2015-04-03 | 2023-04-25 | 马萨诸塞大学 | 用于靶向亨廷汀mRNA的寡核苷酸化合物 |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| WO2017048620A1 (en) * | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| SG10201912902TA (en) | 2015-10-09 | 2020-02-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| CN114685589A (zh) | 2016-03-13 | 2022-07-01 | 波涛生命科学有限公司 | 用于亚磷酰胺和寡核苷酸合成的组合物和方法 |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| MA45290A (fr) | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | Procédés et compositions d'agents biologiquement actifs |
| IL263044B2 (en) | 2016-05-24 | 2024-06-01 | Sarepta Therapeutics Inc | Processes for preparing phosphorodiamidate morpholino oligomers |
| US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| US20190264267A1 (en) | 2016-07-25 | 2019-08-29 | Wave Life Sciences Ltd. | Phasing |
| WO2018098264A1 (en) | 2016-11-23 | 2018-05-31 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| WO2018223056A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2018223073A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2018223081A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| JP7402696B2 (ja) | 2017-06-21 | 2023-12-21 | ウェイブ ライフ サイエンシズ リミテッド | 合成のための化合物、組成物、及び方法 |
| JP7492829B2 (ja) | 2017-06-28 | 2024-05-30 | ロシュ イノベーション センター コペンハーゲン エーエス | 多重カップリングおよび酸化の方法 |
| EP3664816A4 (en) | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES |
| AU2018333065B2 (en) | 2017-09-18 | 2024-04-18 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
| SG11202003126VA (en) | 2017-10-04 | 2020-05-28 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and uses thereof |
| WO2019075357A1 (en) | 2017-10-12 | 2019-04-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| UY38003A (es) | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| AU2019252680B2 (en) | 2018-04-12 | 2025-11-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| TWI869213B (zh) | 2018-09-19 | 2025-01-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| JP2022513719A (ja) | 2018-12-06 | 2022-02-09 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| CA3126845A1 (en) | 2019-02-01 | 2020-08-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| US20230089442A1 (en) | 2019-03-20 | 2023-03-23 | Pachamuthu Kandasamy | Technologies useful for oligonucleotide preparation |
| JPWO2020196662A1 (enExample) | 2019-03-25 | 2020-10-01 | ||
| CA3137740A1 (en) | 2019-04-25 | 2020-10-29 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| MX2021012981A (es) | 2019-04-25 | 2022-01-18 | Wave Life Sciences Ltd | Composiciones de oligonucleotido y metodos de uso de las mismas. |
| CN114502177A (zh) | 2019-05-09 | 2022-05-13 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| US20230220384A1 (en) | 2019-10-06 | 2023-07-13 | Prashant Monian | Oligonucleotide compositions and methods of use thereof |
| WO2021071788A2 (en) | 2019-10-06 | 2021-04-15 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| TW202138559A (zh) | 2019-12-16 | 2021-10-16 | 美商阿尼拉製藥公司 | 含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法 |
| CN115210377A (zh) | 2020-03-01 | 2022-10-18 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| US12054718B2 (en) | 2020-03-26 | 2024-08-06 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use |
| US20230203087A1 (en) | 2020-05-22 | 2023-06-29 | Pachamuthu Kandasamy | Oligonucleotide compositions and methods thereof |
| EP4200616A1 (en) | 2020-08-24 | 2023-06-28 | Wave Life Sciences Ltd. | Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays |
| US20230329201A1 (en) | 2020-08-24 | 2023-10-19 | Wave Life Sciences Ltd. | Cells and non-human animals engineered to express adar1 and uses thereof |
| KR20230118716A (ko) | 2020-11-08 | 2023-08-11 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 조성물 및 이의 방법 |
-
2018
- 2018-06-01 WO PCT/US2018/035721 patent/WO2018223081A1/en not_active Ceased
- 2018-06-01 EP EP18810368.3A patent/EP3630789A4/en active Pending
- 2018-06-01 CN CN201880049516.1A patent/CN110997692B/zh active Active
- 2018-06-01 JP JP2019566839A patent/JP7557941B2/ja active Active
- 2018-06-01 CA CA3065523A patent/CA3065523A1/en active Pending
- 2018-06-01 TW TW107119084A patent/TW201904587A/zh unknown
- 2018-06-01 US US16/618,001 patent/US11597927B2/en active Active
- 2018-06-01 CN CN202411895814.6A patent/CN120249271A/zh active Pending
-
2023
- 2023-03-03 US US18/178,470 patent/US20240175018A1/en active Pending
-
2024
- 2024-04-25 JP JP2024071889A patent/JP2024099745A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024099745A5 (enExample) | ||
| JP2023145620A5 (enExample) | ||
| JP2020522265A5 (enExample) | ||
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP2024081668A5 (enExample) | ||
| JP2020524485A5 (enExample) | ||
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2025041652A5 (enExample) | ||
| DE69838294T2 (de) | Verfahren zur Herstellung von Nukleinsäurekonstrukten | |
| JP2016520312A5 (enExample) | ||
| JP2025160237A5 (enExample) | ||
| JP2018536689A5 (enExample) | ||
| JP2020188756A5 (enExample) | ||
| JP2017532038A5 (enExample) | ||
| CN100400045C (zh) | 基于核酸的化合物及其使用方法 | |
| JP2020500929A5 (enExample) | ||
| JP2018529732A5 (enExample) | ||
| JPWO2020061177A5 (enExample) | ||
| JP2018520685A5 (enExample) | ||
| CN106795096A (zh) | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 | |
| JPWO2019183164A5 (enExample) | ||
| JP2008543854A5 (enExample) | ||
| JP6771387B2 (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JP2013502442A5 (enExample) | ||
| JP2019533472A5 (enExample) |